epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-301, Phase III. Recruiting
Non-small cell lung cancer, second line
NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.
When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.
Study and plan
Northwind Therapeutics (fictional), Phase III, Oncology. Month 0 is January 2025.
Randomise 400 (drop-out 15%) and screen about 667 (screen failure 40%)
Jan 2028
Confidence wanted
Sites per countryEdit the site counts in the table below
How much sites differSpread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
Central finish (P50)Aug 2027month 31.5
Fast case (P10)Mar 2027month 26.4
Slow case (P90)Mar 2028month 38.7
Chance of meeting the deadline80%wanted 85%
Sites15926% likely to recruit nobody
Patients to screen667to randomise 400
On course to finish in August 2027, five months before the deadline
EPI-301, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far
Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
Month
Fast case
Central
Slow case
Actual
Jan 2025
0
0
0
0
Apr 2025
0
0
0
0
Jul 2025
4
2
0
1
Oct 2025
25
17
10
12
Jan 2026
68
50
35
45
Apr 2026
128
97
70
80
Jul 2026
198
150
111
124
Oct 2026
271
207
153
171
Jan 2027
341
261
195
–
Apr 2027
400
317
236
–
Jul 2027
400
372
278
–
Oct 2027
400
400
319
–
Jan 2028
400
400
362
–
Apr 2028
400
400
400
–
Jul 2028
400
400
400
–
Oct 2028
400
400
400
–
Jan 2029
400
400
400
–
Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.
How likely is it to finish by a given month?
A four-in-five chance of finishing by January 2028
Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 80 of 100 dots finish in time
Drag the handle or
In time: 80%Median Aug 2027Late: 20%
Source: epiClinical Poisson-gamma simulation
Show data
Chance that recruitment is complete by the end of each month
Month
Chance complete by then
Jan 2025
0%
Apr 2025
0%
Jul 2025
0%
Oct 2025
0%
Jan 2026
0%
Apr 2026
0%
Jul 2026
0%
Oct 2026
0%
Jan 2027
2%
Apr 2027
14%
Jul 2027
37%
Oct 2027
62%
Jan 2028
80%
Apr 2028
91%
Jul 2028
96%
Oct 2028
98%
Jan 2029
99%
Countries
Use
Country
Patients per site per month
Sites open between
Cap
Sites
Patients by finish
United States
0.091
Therapeutic area: 0.350 Oncology baseline
Country: ×0.75 United States
Site type: ×0.988 Usual mix in United States
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
Patient acceptability: ×1 No effect from the answers
Competing trials: ×0.75 Heavy competition ×0.75
month 4.1 to 10.2
100
110
United Kingdom
0.102
Therapeutic area: 0.350 Oncology baseline
Country: ×0.85 United Kingdom
Site type: ×0.975 Usual mix in United Kingdom
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
Patient acceptability: ×1 No effect from the answers
Competing trials: ×0.75 Heavy competition ×0.75
month 4.0 to 10.0
44
62
Spain
0.121
Therapeutic area: 0.350 Oncology baseline
Country: ×1 Spain
Site type: ×0.977 Usual mix in Spain
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
Patient acceptability: ×1 No effect from the answers
Competing trials: ×0.75 Heavy competition ×0.75
month 7.6 to 13.6
71
87
Poland
0.178
Therapeutic area: 0.350 Oncology baseline
Country: ×1.4 Poland
Site type: ×1.028 Usual mix in Poland
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
Patient acceptability: ×1 No effect from the answers
Competing trials: ×0.75 Heavy competition ×0.75
month 11.1 to 17.1
41
76
Turkey
0.119
Therapeutic area: 0.350 Oncology baseline
Country: ×1 Turkey
Site type: ×0.965 Usual mix in Turkey
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
Patient acceptability: ×1 No effect from the answers
Competing trials: ×0.75 Heavy competition ×0.75
month 6.0 to 12.0
18
32
India
0.129
Therapeutic area: 0.350 Oncology baseline
Country: ×1.1 India
Site type: ×0.952 Usual mix in India
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
Patient acceptability: ×1 No effect from the answers
Competing trials: ×0.75 Heavy competition ×0.75
month 6.0 to 12.0
15
34
Country risks to weigh when choosing sites
United States
Two sourced risks
All sites
The first US site opens quickly, but the rest of the US sites open slowly.
The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B
Tightens: site activation overdue
All sites
Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.
Racial and ethnic under-representation · PB-12 · grade A
United Kingdom
Two sourced risks
Some sites
Costing and contracting were the longest start-up step; the national contract has shortened it.
Fragmented, negotiated costing and contracting · POL-03 · grade A
If it recurs
The regulator's backlog of 2023 was cleared, but could recur.
Regulator assessment backlog · POL-02 · grade A
Spain
Two sourced risks
All sites
Site contracts took 117 days in 2016 and about 90 after national templates.
Fragmented, negotiated costing and contracting · POL-03 · grade A
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
Poland
Two sourced risks
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
All sites
A central ethics committee reviews every study; its effect on timelines is not measured.
Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B
Turkey
Four sourced risks
All sites
Ethics committees fell from 145 to 49 in 2024, cutting review capacity.
Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B
Tightens: site activation overdue
All sites
A fixed pharmaceutical exchange rate has caused repeated medicine shortages.
Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D
Tightens: study drug at the site
All sites
Start-up time has not been measured since CRO data from 2014 and 2015.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
If it recurs
Sites in the south-east lie in the 2023 earthquake zone.
Major earthquake in a site region · SH-11 · grade C
India
Two sourced risks
All sites
Vulnerable participants in trials of new drugs need an audio-visual record of their consent.
Mandatory audio-visual consent for all participants · RW-03 · grade C
Tightens: consent findings
All sites
Start-up time is unmeasured beyond the statutory 90 working days.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
Tightens: site activation overdue
Risk-register entries; the choice of entries per country is epiClinical's.